Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

To join this study, patients generally need to be between 2 and 17 years old and have a confirmed diagnosis of clear cell sarcoma or a specific type of advanced chondrosarcoma. The cancer must be one that cannot be cured by surgery, or has spread to other parts of the body.

Patients will need to be well enough to take part, as assessed by the medical team. This means they should have generally good health otherwise, with their important organs like the liver and kidneys working properly. They must also have measurable cancer that doctors can keep an eye on to see if the treatment is working.

There are also some specific medical requirements, such as certain blood test results, which the study doctors will explain in detail. Patients cannot have other serious health problems that might make the treatment unsafe. The study team will review all medical information to see if someone is a good fit for the trial.

If you join this study, you will receive the study medicine, Atezolizumab, through a drip into your vein (like a blood transfusion). This treatment will be given on day 1 of a 21-day cycle, meaning you would have it every three weeks. Each treatment session will last between 30 to 60 minutes.

Throughout the study, you will have regular check-ups, which include appointments and several tests. These tests typically involve CT scans (a special X-ray that takes detailed pictures inside your body) to monitor the cancer. You will also have biopsies (small tissue samples taken from the tumour) and blood samples collected to help researchers understand more about your cancer and how the medicine is working. You will continue with this treatment for as long as it is helping you and you are not experiencing severe side effects. After the treatment ends, you will have follow-up appointments for up to 90 days to see how you are doing.